_PRIVATE_LIMITED.webp)
Acme Therapeutics (I) Profile
Key Indicators
- Authorised Capital ₹ 1.80 M
- Paid Up Capital ₹ 1.62 M
- Company Age 23 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.33 Cr
- Satisfied Charges ₹ 7.70 M
- Revenue Growth 4.01%
- Profit Growth -0.14%
- Ebitda -1.64%
- Net Worth 13.16%
- Total Assets 2.26%
About Acme Therapeutics (I)
Acme Therapeutics (I) Private Limited (ATIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 14 March 2001 and has a history of 23 years and ten months. Its registered office is in Panchkula, Haryana, India.
The Corporate was formerly known as Acme Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.80 M and a paid-up capital of Rs 1.62 M.
The company currently has active open charges totaling ₹2.33 Cr. The company has closed loans amounting to ₹7.70 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Kumar, Banshidhar Kanhaiyalal, and Gopal Krishna serve as directors at the Company.
Company Details
-
Location
Panchkula, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232HR2001PTC093261
-
Company No.
014592
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Mar 2001
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Acme Therapeutics (I)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gopal Krishna
|
Director | 01-May-2002 | Current |
|
Sanjay Kumar
|
Director | 21-Oct-2019 | Current |
|
Banshidhar Kanhaiyalal
|
Director | 14-Mar-2001 | Current |
Financial Performance of Acme Therapeutics (I).
Acme Therapeutics (I) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.01% increase. The company also saw a slight decrease in profitability, with a 0.14% decrease in profit. The company's net worth Soared by an impressive increase of 13.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acme Therapeutics (I)?
In 2023, Acme Therapeutics (I) had a promoter holding of 95.69% and a public holding of 4.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Evets Drugs Private LimitedBanshidhar Kanhaiyalal is a mutual person
-
Sriram Healthcare Private Limited
Banshidhar Kanhaiyalal is a mutual person
-
Prosperity Drugs Private Limited
Banshidhar Kanhaiyalal is a mutual person
-
Evets Packaging Private Limited
Banshidhar Kanhaiyalal is a mutual person
-
Evets Glass & Polymer Private Limited
Banshidhar Kanhaiyalal is a mutual person
Charges (Loans)
₹23.33 M
₹7.70 M
Charges Breakdown by Lending Institutions
- Others : 2.33 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Feb 2024 | Others | ₹1.50 Cr | Open |
| 20 Mar 2020 | Others | ₹8.33 M | Open |
| 10 Dec 2015 | Kotak Mahindra Bank Limited | ₹4.20 M | Satisfied |
| 03 Jun 2004 | Punjab National Bank | ₹3.50 M | Satisfied |
How Many Employees Work at Acme Therapeutics (I)?
Acme Therapeutics (I) has a workforce of 302 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acme Therapeutics (I), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acme Therapeutics (I)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
